(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 February 2025 (20.02.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/036493 A1

(51) International Patent Classification:
C07K 16/46 (2006.01)

(21) International Application Number:
PCT/CN2024/112831

(22) International Filing Date:
16 August 2024 (16.08.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/520102 17 August 2023 (17.08.2023) US

(71) Applicant: **SINOMAB BIOSCIENCE LIMITED** [CN/CN]; Unit 303 And 305-307, No. 15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong (CN).

(72) Inventors: **CHONG, Chi Ho**; Unit 303 And 305-307, No.15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong (CN). **LEUNG, Shui On**; Unit 303 And 305-307, No.15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong (CN). **CHIU, Pang Sum**; Unit 303 And 305-307, No.15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong (CN).

(74) Agent: **IPRTOP PATENT AND TRADEMARK LAW OFFICE**; Room 7028, 7th Floor, No. 6, Lane 600, West Yunling Road, Putuo District, Shanghai 200333 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/036493 A1

(54) Title: ANTIBODIES TARGETING RANKL AND SCLEROSTIN AND USES THEREOF

(57) Abstract: It provides bispecific antibodies targeting both human RANKL and sclerostin. Polynucleotides encoding the bispecific antibodies, pharmaceutical compositions comprising the bispecific antibodies, and methods of producing the bispecific antibodies are also provided herein. Medical uses of the bispecific antibodies described herein are also disclosed.